Cargando…

Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis

Background and Aims: Although different kinds of traditional Chinese medicines could reportedly improve the efficacy of antiviral therapy on liver fibrosis caused by HBV, the problem of clinicians on how to choose the appropriate treatment strategies for the patients fails to be solved. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yun-kai, Fan, Hai-na, Hu, Yong-hong, Zhao, Zhi-min, Liu, Chenghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399442/
https://www.ncbi.nlm.nih.gov/pubmed/36034853
http://dx.doi.org/10.3389/fphar.2022.943063
_version_ 1784772522387963904
author Dai, Yun-kai
Fan, Hai-na
Hu, Yong-hong
Zhao, Zhi-min
Liu, Chenghai
author_facet Dai, Yun-kai
Fan, Hai-na
Hu, Yong-hong
Zhao, Zhi-min
Liu, Chenghai
author_sort Dai, Yun-kai
collection PubMed
description Background and Aims: Although different kinds of traditional Chinese medicines could reportedly improve the efficacy of antiviral therapy on liver fibrosis caused by HBV, the problem of clinicians on how to choose the appropriate treatment strategies for the patients fails to be solved. This study aims at comparing and ranking different traditional Chinese medicine (TCM) therapies in the treatment of liver fibrosis due to chronic hepatitis B (CHB). Methods: Eight electronic databases were searched from their establishment to 17 Aug 2021. All included data and pooled odds ratio were used for network meta-analysis (NMA) and statistical analysis. The consistency was evaluated by the node-splitting analysis. The stability of results and source of heterogeneity were tested by sensitivity analysis. Different treatment strategies (regimens) in this network meta-analysis were ranked with the aid of surface under the cumulative ranking curve (SUCRA) probability value. Results: A total of 29 articles with 3,106 sufferers were recruited in this NMA. Results of SUCRA value rankings indicated that Fuzheng Huayu therapy or combined with entecavir had preferable effects in improving the clinical efficacy, recovering the level of hyaluronic acid, IV-C, ALT, ALB, and TBil, relieving the TCM symptoms including hypochondriac pain and poor appetite, regaining the width of portal vein and thickness of spleen, and lessening side effects. Apart from these, Ziyin Shugan therapy or combined with ETV could also be suitable to regain the level of laminin, PC-III, and AST, relieve fatigue and HBV-DNA conversion. Conclusion: This NMA confirmed the efficacy and safety of different treatment therapies for improving CHB liver fibrosis, including the serum biomarkers of live fibrosis and serum parameters for liver function, TCM symptoms, imaging indexes, HBV-DNA conversion rate, which offered the TCM practitioners crucial reference value on clinical medication.
format Online
Article
Text
id pubmed-9399442
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93994422022-08-25 Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis Dai, Yun-kai Fan, Hai-na Hu, Yong-hong Zhao, Zhi-min Liu, Chenghai Front Pharmacol Pharmacology Background and Aims: Although different kinds of traditional Chinese medicines could reportedly improve the efficacy of antiviral therapy on liver fibrosis caused by HBV, the problem of clinicians on how to choose the appropriate treatment strategies for the patients fails to be solved. This study aims at comparing and ranking different traditional Chinese medicine (TCM) therapies in the treatment of liver fibrosis due to chronic hepatitis B (CHB). Methods: Eight electronic databases were searched from their establishment to 17 Aug 2021. All included data and pooled odds ratio were used for network meta-analysis (NMA) and statistical analysis. The consistency was evaluated by the node-splitting analysis. The stability of results and source of heterogeneity were tested by sensitivity analysis. Different treatment strategies (regimens) in this network meta-analysis were ranked with the aid of surface under the cumulative ranking curve (SUCRA) probability value. Results: A total of 29 articles with 3,106 sufferers were recruited in this NMA. Results of SUCRA value rankings indicated that Fuzheng Huayu therapy or combined with entecavir had preferable effects in improving the clinical efficacy, recovering the level of hyaluronic acid, IV-C, ALT, ALB, and TBil, relieving the TCM symptoms including hypochondriac pain and poor appetite, regaining the width of portal vein and thickness of spleen, and lessening side effects. Apart from these, Ziyin Shugan therapy or combined with ETV could also be suitable to regain the level of laminin, PC-III, and AST, relieve fatigue and HBV-DNA conversion. Conclusion: This NMA confirmed the efficacy and safety of different treatment therapies for improving CHB liver fibrosis, including the serum biomarkers of live fibrosis and serum parameters for liver function, TCM symptoms, imaging indexes, HBV-DNA conversion rate, which offered the TCM practitioners crucial reference value on clinical medication. Frontiers Media S.A. 2022-08-10 /pmc/articles/PMC9399442/ /pubmed/36034853 http://dx.doi.org/10.3389/fphar.2022.943063 Text en Copyright © 2022 Dai, Fan, Hu, Zhao and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Dai, Yun-kai
Fan, Hai-na
Hu, Yong-hong
Zhao, Zhi-min
Liu, Chenghai
Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis
title Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis
title_full Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis
title_fullStr Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis
title_full_unstemmed Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis
title_short Comparison on different traditional Chinese medicine therapies for chronic hepatitis B liver fibrosis
title_sort comparison on different traditional chinese medicine therapies for chronic hepatitis b liver fibrosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399442/
https://www.ncbi.nlm.nih.gov/pubmed/36034853
http://dx.doi.org/10.3389/fphar.2022.943063
work_keys_str_mv AT daiyunkai comparisonondifferenttraditionalchinesemedicinetherapiesforchronichepatitisbliverfibrosis
AT fanhaina comparisonondifferenttraditionalchinesemedicinetherapiesforchronichepatitisbliverfibrosis
AT huyonghong comparisonondifferenttraditionalchinesemedicinetherapiesforchronichepatitisbliverfibrosis
AT zhaozhimin comparisonondifferenttraditionalchinesemedicinetherapiesforchronichepatitisbliverfibrosis
AT liuchenghai comparisonondifferenttraditionalchinesemedicinetherapiesforchronichepatitisbliverfibrosis